Celgene's

US drugmaker Celgene says that its preliminary unaudited results indicate that total revenue in 2007 will increase by more than 50% over the previous year, to $1.4 billion, while adjusted diluted earnings per share are expected to double to $1.05. The company plans to report its full-year 2007 results on January 31. 2008 total revenue growth is targeted to increase more than 30% to $1.8 billion, and adjusted diluted EPS are predicted to increase around 45% to a range of $1.50 to $1.55.

The company said its commercial performance is based on record total revenue and profits supported primarily by the initial launch of the multiple myeloma drug Revlimid (lenalidomide) in several European countries, and supported by compendia listing for patients newly diagnosed with MM in the USA, as well as strong clinical findings across a broad range of blood cancers.

Late last year, the firm agreed to acquire USA-based Pharmion for $2.9 billion in cash and shares to gain control of the predicted blockbuster Vidaza (azacitidine), which is the first drug to extend median survival in myelodysplastic patients. The agent fits well with Celgene's existing portfolio, which includes the MM drugs Thalomid (thalidomide) and Alkeran (melphalan and melphalan HCl), as well as the attention-deficit hyperactivity disorder agents Focalin (dexmethyphenidate) and Ritalin (methylphenidate).